Helus Pharma CEO to Participate in Neuropsychiatry Summit Webinar
News related to:Helus Pharma · 3 min read
NEW YORK and TORONTO, Sept. 21, 2026 /CourierPR/ -- Helus Pharma, a clinical-stage pharmaceutical company committed to developing novel serotonergic agonists, announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, which is taking place virtually on September 23, 2026. The fireside chat will be webcast live on Wednesday, September 23, 2026, at 9:00 a.m. EDT. To register for the webcast, interested parties should click here. A replay of the event will be available on the Company’s investor relations website under the Events & Presentations page.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company dedicated to helping minds heal by developing proprietary novel serotonergic agonists (NSAs). The Company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 clinical development for generalized anxiety disorder. The Company also has an extensive research portfolio of investigational NSAs.
The TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, which is taking place virtually on September 23, 2026, will feature a fireside chat with Michael Halstead, the CEO of Helus Pharma. The webcast of the fireside chat will be available for registration on the Company’s investor relations website and will be webcast live on Wednesday, September 23, 2026, at 9:00 a.m. EDT. A replay of the event will be available on the Company’s investor relations website under the Events & Presentations page.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 clinical development for generalized anxiety disorder. The Company also has an extensive research portfolio of investigational NSAs.
The TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, which is taking place virtually on September 23, 2026, will feature a fireside chat with Michael Halstead, the CEO of Helus Pharma. The webcast of the fireside chat will be available for registration on the Company’s investor relations website and will be webcast live on Wednesday, September 23, 2026, at 9:00 a.m. EDT. A replay of the event will be available on the Company’s investor relations website under the Events & Presentations page.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 clinical development for generalized anxiety disorder. The Company also has an extensive research portfolio of investigational NSAs.
The TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, which is taking place virtually on September 23, 2026, will feature a fireside chat with Michael Halstead, the CEO of Helus Pharma. The webcast of the fireside chat will be available for registration on the Company’s investor relations website and will be webcast live on Wednesday, September 23, 2026, at 9:00 a.m. EDT. A replay of the event will be available on the Company’s investor relations website under the Events & Presentations page.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 clinical development for generalized anxiety disorder. The Company also has an extensive research portfolio of investigational NSAs.
The TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit, which is taking place virtually on September 23, 2026, will feature a fireside chat with Michael Halstead, the CEO of Helus Pharma. The webcast of the fireside chat will be available for registration on the Company’s investor relations website and will be webcast live on Wednesday, September 23, 2026, at 9:00 a.m. EDT. A replay of the event will be available on the Company’s investor relations website under the Events & Presentations page.